Development of Monoclonal Antibodies Against SARS-CoV-2 Nucleocapsid Protein for COVID-19 Antigen Detection
Abstract
Background
The
coronavirus
disease
2019
(COVID-19)
pandemic
underscored
the
global
need
for
reliable
diagnostic
tools
with
quick
turnaround
time
effective
patient
management
and
mitigation
of
virus
spread.
This
study
aimed
to
express
severe
acute
respiratory
syndrome
2
(SARS-CoV-2)
nucleocapsid
protein
produce
monoclonal
antibodies
(mAbs)
against
expressed
protein.
Methods
Following
successful
expression
purification
His-tagged
SARS-CoV-2
N
using
a
wheat
germ
cell-free
system
(WGCFS),
BALB/c
mice
were
immunized,
generated
hybridomas
screened
mAb
production.
Indirect
sandwich
ELISA
used
screen
reactivity
antibody
both
our
recombinant
antigen
commercial
antigen.
mAbs
also
assessed
their
performance
RT-PCR
confirmed
positive
samples
varying
cycle
threshold
(CT)
values
specificity
intracellular
fluid
(ICF)
other
viruses.
Results
Our
demonstrated
high
antigen,
Beta
Omicron
variants.
There
was
no
significant
difference
in
binding
affinity
(p
=
0.12)
0.072)
antigens.
detected
from
clinical
CT
exhibited
cross-reactivity
Conclusion
We
successfully
leveraging
WGCFS
resource-limited
setting.
had
making
it
suitable
candidate
detection
kit
development.
Beyond
diagnostics,
holds
potential
therapeutic
applications
as
well
use
environmental
surveillance
platforms.
Research Square (Research Square), Год журнала: 2025, Номер unknown
Опубликована: Апрель 14, 2025
Язык: Английский